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QMCF technologyHarnessing of a branched structure is a novel approach in the design of cell-penetrating peptides and it has
provided highly efﬁcient transfection reagents for intracellular delivery of nucleic acids. The new stearylated
TP10 analogs, NickFects, condense plasmid DNA, splice correcting oligonucleotides and short interfering
RNAs into stable nanoparticles with a size of 62–160 nm. Such nanoparticles have a negative surface charge
(−11 to −18 mV) in serum containing medium and enable highly efﬁcient gene expression, splice correc-
tion and gene silencing. One of the novel peptides, NickFect51 is capable of transfecting plasmid DNA into
a large variety of cell lines, including refractory suspension and primary cells and in several cases exceeds
the transfection level of commercially available reagent Lipofectamine™ 2000 without any cytotoxic side
effects. Additionally we demonstrate the advantages of NickFect51 in a protein production system, QMCF
technology, for expression and production of recombinant proteins in hardly transfectable suspension cells.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
A search for new compounds that selectively modulate gene ex-
pression in order to treat different human diseases, has been a hot
topic for many years. Nucleic acids, such as double-stranded DNA in
the form of expression plasmids (pDNA), short single-stranded
splice-correcting oligonucleotides (SCO) and double-stranded small
interfering RNAs (siRNA), are highly promising tools for the treat-
ment of many diseases by gene therapy [1–6]. Clinical potential of
these biomolecules remains restricted so far due to their poor stabil-
ity in the presence of serum and low uptake into the cells due to their
high molecular weight, negative charge and hydrophilic nature.
Therefore, the development of efﬁcient delivery systems that are
non-toxic, effective at low doses, easy to manufacture and handle,arge ratio; DLS, dynamic light
ed green ﬂuorescent protein;
-hexaﬂuoro-phosphate; HOBT,
FACS, ﬂuorescence activated
lasmid; pDNA, plasmid DNA;
rfering RNA; TP10, transportan
372 7 37 4900.
.
rights reserved.and which promote rapid endosomal escape after intracellular deliv-
ery in order to reach the target, is vital [7–9].
Cell-penetrating peptides (CPP) is a class of non-viral delivery
vectors that has been used for the intracellular delivery of various
bioactive cargos, including nucleic acids. Numerous groups have
reported their successful delivery of nucleic acids, such as SCOs
[10–13]; siRNA [14–16] and pDNA [17,18], by CPPs in a large variety
of cell lines without evoking toxic or immunogenic side effects.
pDNA and other nucleic acids can be vectorized with CPPs by using
a non-covalent complexation strategy, which in comparison to cova-
lent conjugation is less laborious, cost-efﬁcient and lower concentra-
tions of oligonucleotides are required to achieve a biological response
[19]. However, the limitation of this strategy is the entrapment of
CPP–cargo complexes in endosomes after cellular uptake by endocy-
tosis. To enhance endosomal escape of CPP–cargo complexes from
intracellular compartments, several chemical modiﬁcations have been
introduced into known CPPs [16,17,20]. Developing CPPs with in-
creased endosomolytic properties is a necessary step towards achieving
biological effects at low concentrations for future in vivo applications.
We have demonstrated that addition of hydrophobic stearyl-moiety
to an amphipathic CPP, transportan 10 (TP10), improves the properties
of the peptide as a transport vehicle for nucleic acids, albeit the trans-
fection efﬁcacy was limited due to the entrapment of CPP–cargo com-
plexes in endosomal compartments [12,18]. In the current study we
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modifying its sequence at Lys7, which is the linker between the neuro-
peptide galanin motif and mastoparan residues. We designed and syn-
thesized three new stearylated CPPs, namedNickFects (NF), all of which
upon complexation with nucleic acids formed small stable
nanoparticles and had higher transfection efﬁcacy than stearyl-TP10.
Here we show that one of the peptides, NickFect51 (NF51) proved to
be a surprisingly effective and versatile vehicle for pDNA, SCO and
siRNA intracellular delivery into various adherent and suspension cells
without revealing cytotoxic side effects. Furthermore, we demonstrate
the applicability of NickFect51 in the mammalian protein production
systemnamedQMCF technology, that usesmammalian cells and appro-
priate plasmids for expression of biologically active substances, such as
recombinant proteins, recombinant antibodies, virus like particles; and
for generation of cell based assays for screening of active compounds for
drug development.
Altogether our data suggest that NickFect51 has great potential as
an efﬁcient intracellular delivery vehicle for nucleic acid based phar-
maceuticals and also in custom protein production applications.
2. Materials and methods
2.1. Synthesis of peptides
Peptides were synthesized on an automated peptide synthesiz-
er (Applied Biosystems, USA) using ﬂuorenylmethyloxycarbonyl
(Fmoc) solid-phase peptide synthesis strategy with Rink-amide
methylbenzylhydrylamine resin (loading 0.41 mmol/g) to obtain
C-terminally amidated peptides. The stearic acid was coupled man-
ually to the N-terminus of the peptide overnight, at room temper-
ature with 5 eq. stearic acid. For the synthesis of NF51 and NF53
tert-butyloxycarbonyl (Boc) monomers e.g. Boc-L-Orn(Fmoc)-OH,
Boc-L-Lys(Fmoc)-OH, Fmoc-L-Orn(Boc)-OH (Iris Biotech., Germany)
were used. Reaction was carried out using HOBT/HBTU as coupling
reagents in DMF with DIEA as an activator base. The cleavage was
performed with triﬂuoroacetic acid (TFA), 2.5% triisopropylsilane and
2.5% water for 2 h at room temperature. Peptides were puriﬁed by
reversed-phase high-performance liquid chromatography on C4
column (Phenomenex Jupiter C4, 5 μm, 300A, 250×10 mm) using
a gradient of acetonitrile/water containing 0.1% TFA. The molecular
weight of the peptides was analyzed by matrix-assisted laser
desorption-ionization/time of ﬂight mass spectrometry (The Voyager-
DE™ PRO Biospectrometry™ System, USA). The concentration of the
peptides was determined based on dilutions of accurately weighted
substances.
2.2. Cell culture
Chinese hamster ovary (CHO) cells were grown in Dulbecco's
Modiﬁed Eagles Medium F12 (F12). HeLa pLuc705 was kindly provided
by R. Kole, human embryonic kidney (HEK293), human osteosarcoma
(U2OS), human glioblastoma (U87) cells, and mouse embryonal ﬁbro-
blast (MEF) cells were grown in Dulbecco's modiﬁed Eagles medium
(DMEM), and Jurkat and mouse B lymphoma (A20) cells in RPMI medi-
um (PAA Laboratories Gmbh., Austria). All mediumswere supplemented
with glutamax, 0.1 mM non-essential amino acids, 1.0 mM sodium
pyruvate, 10% fetal bovine serum (FBS), 100 U/ml penicillin, and
100 mg/ml streptomycin (PAA Laboratories GmbH, Germany).
U2OSEBNALTD3 and CHOEBNALT85 are stable cell-lines derived
from U2OS (ECACC, UK) and CHO-S (Invitrogen, USA) cell lines, respec-
tively. The CHOEBNALT85 suspension cells are adapted to a serum-free
suspension culture in QMix1medium (Icosagen, Estonia). For adherent
CHOEBNALT85 Ham's F-12 with stable glutamine (PAA E15-890 or
equivalent) was used. U2OSEBNALTD3 cells were grown in DMEM
supplemented with 10% FBS. All cells were grown at 37 °C in 5% CO2
atmosphere.2.3. Plasmid transfection
5×104 CHO, 6×104 HEK293, 2.5×104 U87 or U2OS cells and
5×104 MEF cells per well were seeded 24 h before the experiment
into 24-well plates. In experiments with adherent modiﬁed
cell-lines 6 well-plates and corresponding amount of cells were
used. For experiments with suspension cells 1×105 Jurkat cells and
5×105 CHOEBNALT85 cells per well were seeded into 24 and 6-well
plates, respectively.
For transfection luciferase expressing plasmid (pGL3) 4.7 kbp,
Mw=3.10 g/mol (Promega, Sweden) or enhanced green ﬂuorescence
protein expressing plasmid pQMCF-CMV-EGFP (EGFP) 6.4 kbp, Mw=
4.224 g/mol (Icosagen, Estonia) at concentration 1 μg/ml were used.
The plasmid was mixed with CPPs at different charge ratios (CR 1–4)
in milliQ H2O in 1/10th of the ﬁnal treatment volume and complexes
were formed for 1 h at room temperature. Cells were treated with
CPP/plasmid complexes for 4 h in serum-free or serum-containing me-
dium. Lipofectamine™ 2000 (Invitrogen, Sweden) and Xfect (Clontech,
US) were used according to the manufacturer's protocols. After 4 h
treatment full growth media was added and incubated for 20 h. In ex-
periments with chloroquine (Sigma, Germany), it was added to the
cells to a ﬁnal concentration of 100 μM directly prior to the treatment
of the cells with preformed NF/pDNA complexes.
In experiments with pGL3 plasmid cells were washed twice with
phosphate buffered saline (PBS), and lysed using 100 μl 0.1% Triton
X-100 in PBS buffer for 30 min at +4 °C. Luciferase activity was mea-
sured in relative light units (RLU) using Promega's luciferase assay
system on GLOMAX™ 96microplate luminometer (Promega, Sweden).
Data was normalized to protein content measured with DC protein de-
termination kit (Bio-Rad Laboratories, Inc., USA).
In experiments with EGFP plasmid media was removed and cells
were rinsed with PBS and detached from the plate using Trypsin/
EDTA in PBS for 5 min at 37 °C, suspended in PBS containing 5% fetal bo-
vine serum (FBS) and ﬂow cytometry analysis (FACS) was carried out
with a BD LSR II ﬂow cytometer (BD Biosciences, San Jose, CA, USA)
equipped with a 488 nm argon laser. Population of viable cells was de-
termined from a scatter plot: forward scattered light (FSC) vs. side
scattered light (SSC) plot. A minimum of 10,000 events from the viable
cell population per sample were analyzed. Data was analyzed using BD
FACS Diva software.
G418 selection was used as standard procedure in QMCF technol-
ogy for selecting a plasmid-containing cell population. During the se-
lection with antibiotics cell culture viability was kept as high as
possible, in most cases it was close to 85% or higher. High cell culture
viability allows fast expansion of the cell culture volume, and approx-
imately 10–20 days after transfection, generation of an expression
cell bank (1×107 cells/vial) was possible.
2.4. Splice correction assay
The delivery efﬁcacy of NickFects for SCOs was evaluated by the
splice-correction assay introduced by R. Kole [21]. 5×104 of HeLa
pLuc705 cells perwell were seeded in 24-well plates 24 h prior to exper-
iments. 2′-OMe oligonucleotides (5′-CCU CUU ACC UCA GUU ACA)
(Microsynth AG, Switzerland), ﬁnal concentration 200 nM, were mixed
with CPPs at different molar ratios (MR 5–10) in MilliQ H2O. Complexes
were formed and cells were treated as described before. In 24 h cells
were lysed and luciferase activity was measured as mentioned above.
2.5. Treatment with siRNA
4×104 of EGFP-CHO cells were seeded in 24-well plates 24 h prior to
experiments. siRNA (5′-GGCUACGUCCAGGAGCGCACC, 3′-UGCGCUCCU
GGACGUAGCCUU), was mixed with CPP at different molar ratios
(MR 5–30) inMilliQ H2O. Complexes were formed and cells were treat-
ed as described afore. After indicated time media was removed, cells
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containing 5% FBS and FACS analysiswas performed as described above.
2.6. Toxicity measurements
Cell viability was analyzed by CytoTox-Glo™ Assay (Promega,
Sweden). 1×104 MEF, Jurkat, Hela pLuc 705 or EGFP-CHO cells were
seeded into 96-well plates 24 h before the experiment. Complexes
were formed and cells were treated as described before in serum-free
medium for 4 h. Subsequently 100 μl of serum-containing medium
was added to cells. 24 h after treatment the number of dead cells was
measured on GLOMAX™ 96 microplate luminometer and normalized
to the number of cells.
2.7. Dynamic light scattering (DLS) and zeta-potential measurements
Hydrodynamicmean diameter and ξ-potential of the nanocomplexes
was determined by dynamic light scattering studies using a Zetasizer
Nano ZS apparatus (Malvern Instruments, United Kingdom). Peptide/
cargo complexes were prepared in MilliQ H2O according to the protocols
for transfection and diluted in Opti-MEM (Invitrogen, Sweden) with 10%
fetal bovine serum. All resultswere based on three or fourmeasurements
from two independent samples. All data were converted to “relative by
intensity” plots from where the mean hydrodynamic diameter was
derived.
2.8. Transmission electron microscopy
For transmission electron microscopy (TEM) studies the nanogold-
labeled 705 pLuc splice-correcting oligonucleotides (NG-SCO) were
used. The thiol group at 5′ end of SCO was tagged with nanogold cluster
(Monomaleimido Nanogold, Nanoprobes, NY, d 1.4 nm) by forming a
covalent bond between the thiol group of oligonucleotide and the
maleimide group of label. The non-covalent complexes of NF51 with
NG-SCO were formed as for splice correction experiments described
above. HeLa pLuc 705 were treated with NF51/NG-SCO complexes at
MR 7 for 1 to 4 h at 37 °C. Cells were then ﬁxed and the nanogold label
was magniﬁed by silver enhancement followed by stabilization with
0.05% gold chloride. After postﬁxation with osmium tetraoxide the cells
were dehydrated and embedded in epoxy resin. Ultrathin sections were
cut in parallel with the coverslip, post-stained with uranyl acetate a
lead citrate, and examined with JEM-100S (JEOL, Japan) transmission
electron microscope. The scanned TEM images were analyzed and
processed with Adobe Photoshop CS4 software.
2.9. Statistics
Values in all experiments are represented as mean±SEM of at
least 3 independent experiments performed in duplicate.
3. Results
3.1. Design of NickFects
To improve the properties of stearyl-TP10 as a transport vehicle for
intracellular delivery of nucleic acids we implemented modiﬁcations
on Lys7, which is the linker between a neuropeptide galanin motif
and mastoparan residues in TP10 peptide sequence. As a ﬁrst modiﬁca-
tion, we replaced lysine7 with ornithine, to obtain NF53 (Fig. 1).
Secondly, we used ε-NH2 group of Lys7 for subsequent synthesis in-
stead of α-NH2 used ordinarily, yielding NF61. Thereafter, these above
mentioned 2 modiﬁcations were implemented simultaneously. We
obtainedNF51 by replacing Lys 7with ornithine and continuing synthe-
sis by coupling Gly6 to δ-NH2 group of ornithine.3.2. NickFects form stable nanoparticles with nucleic acids
To assess whether NickFects form stable nanoparticles with nucleic
acids (pDNA, SCO, siRNA) by simply mixing the substances in water,
dynamic light scattering analysis (DLS) was performed. DLS measure-
ments corroborated that NickFects packed plasmid DNA, splice
correcting oligonucleotides and siRNAmolecules inwater into homoge-
neous, unimodal nanoparticles, with the sizes of 60–160 nm (Table 1).
In the presence of serum NickFects/nucleic acid nanoparticles retained
their size and displayed a negative surface charge, in the range from
−11 to−18 mV.
3.3. NickFects deliver pDNA into different cell types and transfect the
whole cell population
To study the efﬁcacy of NickFects in conveying pDNA into cells,
peptides were complexed with the luciferase-encoding plasmid
(pGL3) and luciferase activity was measured 24 h after the treatment
in CHO cells and compared with the efﬁcacy of stearyl-TP10. NF53
and NF61 lead to 10–100 fold higher plasmid transfection than
stearyl-TP10 (Fig. 2a) and NF51 yielded 1000-fold higher luciferase
gene expression level in serum free medium. Next we evaluated the
potential of NF51 to convey pDNA into different normal and cancer
cells. Widely used lipid-based transfection reagent Lipofectamine™
2000 (LF2000) was utilized as a positive control.
NF51 demonstrated high pDNA transfection efﬁciency in all tested
adherent cell lines (Fig. S1a–d). In CHO cells NF51 lead to higher gene ex-
pression than LF2000 even in serum containing medium. In human can-
cer cell lines, U2OS and U87, in serum free medium NF51 reached the
transfection efﬁcacy of LF2000. However, in HEK cells, gene expression
remained 10–100 fold lower than that achieved with LF2000. Moreover,
NF51was capable of delivering pDNA into hard-to-transfect cells, such as
mouse embryonic ﬁbroblast (MEF) cells, T and B lymphocyte cells, Jurkat
and A20, respectively (Fig. 2b–d). In MEF cells NF51 mediated luciferase
expression, which exceeded transfection level achieved by LF2000 in
serum-free medium and resulted in 1000 fold improvement over con-
trol. In the presence of serum the transfection level achieved by LF2000
exceeded that of NF51 only 5 fold. In Jurkat and A20 cells NF51mediated
pDNA transfection in serum freemediumwas at the same level than ex-
pression achieved by LF2000 and in the presence of serumproteins NF51
mediated 10 fold higher gene expression compared to untreated cells.
An important feature for a delivery vector is the ability to transfect
entire cell populations. The number of transfected cells was veriﬁed
by delivering NF51/EGFP encoded plasmid complexes into different
cell lines and quantitatively estimating the number of cells by ﬂow cy-
tometry analysis (Fig. S1e). 24 h after single treatment in serum-free
medium more than 80% and in serum containing medium 45% of CHO,
U87, and U2OS cell populations were transfected with reporter gene.
Remarkably, the transfection efﬁcacy was not dependent on cell
conﬂuency as veriﬁed in experiments with cells grown at different
conﬂuency (data not shown).
3.4. NF51 is an efﬁcient transfection reagent for protein production
Uniqueness of the QMCF technology is the opportunity to generate
a protein expressing cell line within a couple of weeks without a need
for the integration of an expression cassette of the protein of interest
into the genome and further time consuming clonal-selection. Cell
lines used in QMCF technology stably express mouse Polyomavirus
(Py) large T antigen and Epstein–Barr virus EBNA-1 protein, which
bound to the speciﬁc DNA sequences. Py minimal origin of replication
and family of repeat sequence in the expression plasmid assures
thereby a stable replication and maintenance/segregation of the ex-
pression plasmid.
In the currentwork, we tested NF51 applicability in QMCF technology
bydelivering pQMCF-CMV-EGFPplasmid into adherentU2OSEBNALTD3,
Fig. 1. Structures of NickFects: NF51, NF53, NF61 (stearyl moiety is CH3–(CH2)16–CO–).
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ment of the cells with NF51/pDNA complexes for 24 h, approximately
50% of the adherent cell population was transfected with the reporter
gene in both tested cell lines (Fig. 3a). More importantly, the percentage
of EGFP positive cells reached the 95% at the 7th day of culturing
transfected cells under selective conditions. NF51 exhibited no toxic ef-
fect and cell population recovered from the treatment rapidly. NF51
was also capable of transfecting suspension cells and in 40 h after treat-
ment the gene expression was detectable in 70% of CHOEBNALT85 sus-
pension cells (Fig. 3b). Such transfection level was achieved with NF51
at a very modest amount of pDNA (0.5 μg) while with the commercially
available transfection reagent Xfect the same transfection level was
reached only at a higher (2 μg) quantity of pDNA. With widely used
liposome-based transfection reagent LF2000 only 45% of the cells were
transfected with EGFP even at 2 μg of pDNA.Table 1
Average diameter and Zeta potential of NickFects/nucleic acids nanoparticles determined by
(CR) and molar ratios (MR). In 1 h nanoparticles' average size (size, nm±SD) and surface c
10% of fetal bovine serum (FBS).
Peptide/pDNA
CR3
NF51 Water Size 62.0±0.2
PdI 0.138
Optimem+FBS Size 121.4±8.1
PdI 0.623
ξ-pot −11.5±2.5
NF53 Water Size 74.3±5.9
PdI 0.360
Optimem+FBS Size 86.6±16.5
PdI 0.613
ξ-pot −14.9
NF61 Water Size 68.7±4.5
PdI 0.200
Optimem+FBS Size 177.9±7.9
PdI 0.638
ξ-pot −17.93.5. NickFects mediate effective splicing modulation
The delivery efﬁcacy of splice-correcting oligonucleotides by
NickFects was evaluated by a positive read-out splice-correction assay.
NF61 induced SCO intracellular delivery similarly with stearyl-TP10,
while NF53 mediated splice-correction at a modest level (Fig. 4a, b).
Meanwhile NF51 induced 4–5 times higher splice correction levels
than stearyl-TP10 and even exceeded the activity of LF2000, both in
the absence and in the presence of serum.
The uptake of NF51/SCO nanocomplexes was also assessed by
confocal microscopy analysis. NF51/SCO complexes internalized into to
Hela pLuc705 cells effectively and 4 h after treatment the complexes
were detectable inside the cells and in 24 h also in the cell nuclei (Fig. S2).
3.6. NickFects/siRNA nanoparticles induce gene knockdown
Subsequently, the ability of NickFects to facilitate siRNA intracellular
delivery was tested. CHO cells stably expressing EGFP protein were
treated with NF/EGFP-siRNA complexes at different molar ratios and
the percentage of cells that underwent RNAi was measured by ﬂow cy-
tometry. NF53 and NF61mediated EGFP gene downregulationmore ef-
ﬁciently than Lipofectamine™ 2000 and Lipofectamine™ RNAiMAX in
serum-free medium, and they retained similar efﬁcacy level as LF2000
in the presence of serum (Fig. 5a). NF51/siRNA nanoparticles mediated
gene silencing of nearly whole cell population in serum-free medium
and 60% of the cell population in the presence of serum. NF51
transfected siRNA into cells at low peptide concentrations, ranging
from 0.5 to 1 μM, and for achieving efﬁcient gene knockdown low
amounts of siRNA (25–50 nM) were needed (Fig. 5b and Fig. S3c). The
maximum silencing of the target population was achieved within 48 h
after single treatment of cells with NF51/siRNA nanoparticles (Fig.
S3a). In the absence of serum proteins the entire cell populations
underwent RNAi within 48 h as determined by the complete shift in
the FACS histograms (Fig. S3b). In contrast, a substantial fraction of
the target population was not silenced by lipofection.
3.7. NickFects are non-toxic delivery vectors
Another requirement for the use of a delivery vector in biological ap-
plications is the absence of cellular toxicity. Cell viability upon the treat-
ment of the cells with NickFects/cargo nanocomplexes was assessed
with CytoTox-Glo™ assay. Complexed with pDNA NF51 reduced viabil-
ity of MEF and Jurkat cells less than 30% and NF53 nearly 15%, while
LF2000 reduced cell viability 50% (Fig. S4a, b). All NickFects exhibitedDLS measurements. NickFects and nucleic acids were mixed at different charge ratios
harge (ξ-pot, mV±SD) were measured in water and in Opti-MEM supplemented with
Peptide/SCO
MR 10
Peptide/siRNA
MR10
Size 86.0±14.7 Size 74.2±6.7
PdI 0.298 PdI 0.197
Size 168.1±12.2 Size 94.4±1.2
PdI 0.637 PdI 0.596
ξ-pot −11.1±2.4 ξ-pot −11.8±0.5
Size 135.3±7.8 Size 68.6±8.7
PdI 0.459 PdI 0.529
Size 85.3±13.4 Size 78.9±3.9
PdI 0.582 PdI 0.575
ξ-pot −8.8 ξ-pot −11.9
Size 60.5±9.3 Size 159.4±9.9
PdI 0.286 PdI 0.348
Size 94.9±9,8 Size 110.9 ±
PdI 0.666 PdI 0.608
ξ-pot −10.2 ξ-pot −13.6
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Fig. 2. Plasmid transfection efﬁcacy of NickFects. a) NickFects and stearyl-TP10 mediated pDNA delivery in CHO cells in serum free medium. b–d) Delivery efﬁcacy of NF51/pDNA
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while Lipofectamine™ 2000 reduced cell viability 35–45% (Fig. S4c, d).
3.8. NF51-cargo nanoparticles are able to escape from endosomes
In order to further characterize the NF51/nucleic acid nanoparticles
and to gain better insight into their membrane interaction, cellular
uptake and trafﬁcking inside cells on the ultrastructural level we used
transmission electron microscopy. The complexes of NF51/SCO were
detected as small distinct particles located sparsely at the surface of
HeLa pLuc705 cells (arrows in Fig. 6a and b). The particles were not
very uniform and had sizes from about 80 to 170 nm (inset in Fig. 6a),
and were rather loosely packed judging by the relatively low electron
density of nanoparticles. Already after 30 min of incubation the
number of the complexes in cells was markedly higher than on theU2
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Fig. 3. Application of NF51 in protein production system. Number of transfected cells with p
and CHOEBNALT85A cells in 24 h and 7 days after single treatment; b) suspension CHOEBNA
ratio 2 in 48 h after single treatment compared to Xfect and LF2000.plasma membrane suggesting a rapid cellular uptake. The NF51/SCO
nanoparticles entered cells mainly by endocytosis and inside cells, the
majority of complexes localized in large (400–500 nm) vesicles (Fig. 6c)
and retained a nanoparticle-like structure. Often the nanoparticles
were in close association with the endosomal membrane, and in some
vesicles induced the disruption of endosomal membrane and escape
to the cytosol (Fig. 6d). At 1 h of incubation many endosomes had lost
intactness (arrowheads in Fig. 6c) and nanogold particleswere detected
in the cytoplasm (arrows in Fig. 6f) suggesting escape of SCO into the
cytosol. Later, starting from 4 h, SCO had also reached the cell nuclei
(inset in Fig. 6e).
The ability of NF51/cargo complexes to escape from endosomes
was also conﬁrmed by pDNA transfection experiments in the pres-
ence and absence of chloroquine (Fig. S5). Lysosomotropic agent
chloroquine did not inﬂuence the gene expression mediated by0.5 1 2
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Fig. 4. Transfection of splice-correcting oligonucleotides by NickFects. Resque of luciferase expression by a splice correction in Hela pLuc 705 cells induced by SCO complexed with
a) NickFects and stearyl-TP10 at molar ratio 10, and b) NF51 in a dose dependent manner. Concentration of SCO was 200 nM. Lipofectamine™ 2000 was used as a positive control.
Results are presented as fold-increase over untreated cells.
1370 P. Arukuusk et al. / Biochimica et Biophysica Acta 1828 (2013) 1365–1373NF51 neither in the absence nor in the presence of serum. In a con-
trast 10-fold increase in pDNA transfection level was induced by chlo-
roquine in the case of stearyl-TP10/pDNA complexes.4. Discussion
Triggering of mRNA degradation by short interfering RNAs or deliv-
ering pDNA,which codes for a protein that is insufﬁciently or aberrantly
expressed, offers a great potential to treat various diseases, e.g. viral and
genetic diseases or cancer [22,23]. In addition, numerous genetic
diseases in humans are caused by mutations affecting alternative
pre-mRNA splicing amenable to splice switching by oligonucleotides
that restore correct splicing as well as rescue the function of the defec-
tive gene [6]. The key factor for the application of nucleic acids as ther-
apeutics is to overcome the problems concerning delivery of these
active biomolecules to intracellular targets.
CPP are non-viral vectors facilitating the delivery of various biomol-
ecules across biological barriers. CPPs have been shown to condense
nucleic acids via electrostatic and hydrophobic interactions [24], but
despite the effective ability of nanoparticle formation the relative trans-
fection efﬁciencies have usually remained lower than that of lipofection
[17]. The majority of CPPs and their cargos are taken up by different
endocytic pathways [25]. In order to become bioactive the complexes
must ultimately escape from the endosomes and nucleic acids should
reach their site of action in the cytosol or nucleus. The main drawback
while using CPPs is the entrapment of peptide–cargo complexes in the
endosomal compartments [26] and to overcome this limitation, differ-
ent approaches have been utilized [16,27].U
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Fig. 5. Gene knockdown by NickFects/siRNA nanoparticles. RNAi response in EGFP-CHO cell
siRNA, molar ratio 10, controls Lipofectamine™ 2000and Lipofectamine™ RNAiMAX were us
at different siRNA concentrations (12.5–100 nM).Our previous studies demonstrated that stearylation of amphi-
pathic peptide TP10 at N-terminus reﬁnes its carrier properties
and stearyl-TP10 was able to deliver SCO and pDNA into different
cell-lines by using a non-covalent co-incubation strategy [12,18]. In
the current work we further developed stearyl-TP10 as a delivery ve-
hicle for nucleic acids by improving its ability to form particles,
endosomolytic properties and the stability in the presence of serum.
We implemented two new chemical modiﬁcations in stearyl-TP10
sequence. The ﬁrst modiﬁcation was inspired by poly-L-ornithine's
higher ability to condense DNA and therefore its superior transfection ef-
ﬁciency compared to equivalent poly-L-lysine-based systems [28,29].
Moreover, ornithine, as a non-coded amino acid is less susceptible to
serum proteases and increases the stability of the peptide in a serum
containing environment. The rationale behind the second modiﬁcation
was the higher transfection efﬁcacy of ε-poly-L-Lys compared to
α-poly-L-Lys due to the ability of the latter to form smaller particles
with pDNA and to promote efﬁcient endosomal escape [30].
Our results emphasize that both introduced modiﬁcations were
well-justiﬁed and all new peptides surpassed the efﬁcacy of stearyl-
TP10 for intracellular delivery of nucleic acids [18]. NickFects con-
densed nucleic acids into 60–160 nm sized stable complexes that
retained constant size in the presence of serum, suggesting that
they should meet the size criteria for in vivo applications [31].
Remarkably high transfection level was achieved with NF51, which
enabled highly efﬁcient pDNA intracellular delivery in all tested cell
lines, including hard to transfect cell lines, e.g., T and B lymphocytes,
and mouse embryonic ﬁbroblast cells. In several cell lines the gene
expression obtained with NF51/pDNA complexes even exceeded the
transfection level achieved by LF2000. Moreover, NF51 enabled the0
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s measured by FACS analysis 48 h after single treatment with a) NickFects and 100 nM
ed according to manufacturer's protocol and b) NF51/siRNA complexes, molar ratio 10,
Fig. 6. Electron microscopy images of the interaction with plasma membrane and intracellular localization of NF51/SCO complexes. HeLa pLuc 705 cells were incubated with
nanogold-labeled SCO/NF51 complexes for 30 min (a, b) or 4 h (c–e). Interaction of NF51/SCO nanoparticles with cell surface (arrows on a and b, enlarged inset on a) and local-
ization in endosomal structures (c). (d) NF51/SCO complexes in vesicle with disrupted membrane (magniﬁed image from c) and inside nucleus (enlarged inset on e). Arrow on
(e) indicates cellular uptake of NF51/SCO complexes in endocytic vesicle. Scale bar 500 nm; n, nucleus.
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feasible by using lipofection.
Aberrant pre-mRNA splicing is involved in various diseases, and the
blockage of aberrant splice sites by SCO has a signiﬁcant therapeutic po-
tential. Performing confocal and transmission electron microscopy
analysis and positive read-out splice correction assay results all corrob-
orated NF51-mediated SCO uptake to the cells and cell nucleus where
splicing takes place. Even in the presence of serumNF51 induced higher
splice correction than Lipofectamine™ 2000.
Despite great progress in the use of siRNA as therapeutics, only a
handful of papers have reported on successful CPP-facilitated siRNA
delivery [15,16,32–35]. NF51 formed small 74 nm sized nanoparticles
with siRNA which entered quickly into the cells and transfected the
whole cell population, whereas the target gene population was si-
lenced by lipofection only partially. Maximal silencing in the target
population was achieved in 48 h after a single treatment, and impor-
tantly, for effective gene downregulation very low concentrations of
peptide (0.5–1 μM) and siRNA (25–50 nM) were needed.
As demonstrated in several studies, the high transfection efﬁcacy is
often associated with increased cellular toxicity, e.g. widely used re-
agent Lipofectamine™ 2000 signiﬁcantly reduces cell viability at con-
centrations suggested by the manufacturer [36]. None of the NickFects
revealed substantial cytotoxic effects to cells at used concentrations. Al-
though NF51 yielded a transfection efﬁcacy comparable to or even
higher to that of LF2000, the high transfection efﬁcacy of the peptide
was not accompanied by increased cytotoxicity.In parallel with the quantitative analysis of NF51/nucleic acid
nanoparticles by DLS we assessed by electron microscopy, whether
all sizes of nanoparticles are engulfed by cells or preferentially only
a certain fraction of them is internalized. The nanogold labeled SCO
complexed with NF51 formed small nanoparticles with diameters
about 80 to 170 nm, which were by electron microscopy rarely
detected on the cell surface but abundantly in cells. Both DLS and
TEM reported the same size for NF51/nucleic acid nanoparticles,
suggesting that despite of being less uniform or homogenous than
stearyl-TP10/SCO nanoparticles, they are sufﬁciently stable in serum
containing medium and on the cell surface. However, NF51 seems to
organize SCOs into less tightly packed nanostructures since the electron
density of particles was relatively low and single gold clusters are locat-
ed at a distance from each other. The number of nanoparticles on the
cell surfacewas very small compared to the amount of complexes inside
cells, suggesting rapid and efﬁcient cellular uptake.Most of the internal-
ized complexes were detected in endososomal structures, but impor-
tantly, a considerable fraction of them had still escaped to the cytosol
and reached the nucleus. It is reasonable to speculate that less densely
packed NF51/oligonucleotide particles might dissociate into smaller
clusters more easily and better translocate into the nucleus.
The main limiting step in the bioavailability of nucleic acids as
therapeutics is the endosomal entrapment of CPP/cargo complexes. The
lysomotropic agent chloroquine induces osmotic swelling and promotes
disruption of endosomal compartments and subsequently endosomal
release of CPP/cargo complexes. Both chemical modiﬁcations introduced
1372 P. Arukuusk et al. / Biochimica et Biophysica Acta 1828 (2013) 1365–1373in the sequence of stearyl-TP10, signiﬁcantly augmented the endosomlytic
properties of NF51, as chloroquine did not increase the biological
response obtained with NF51 as supposed to when the particles were
entrapped in the endosomes.
Based on our ﬁndings that NF51 is a highly efﬁcient and non-toxic
transfection reagent for nucleic acids both in adherent and suspension
cells, we estimated the applicability of NF51 in the mammalian protein
production system, a QMCF technology, established by Icosagen Cell
Factory. Comparing with transient protein production technologies
where the expression of the protein of interest decreases in a few
days after transfection, the copy number of QMCF expression plasmids
and the expression of the protein of interest remains stable during a
period of two months or longer of continuous culturing under selective
conditions. Themain advantage of QMCF technology is the possibility to
generate the expression cell banks within 2–3 weeks after transfection.
There are certain requirements for the transfection reagent to be
applicable in QMCF technology: it has to be non-toxic and gentle to del-
icate suspension and adherentmodiﬁed cells, and it has to transfect the
whole cell population. NF51 effectively facilitated pDNA intracellular
delivery and 7 days after a single treatment almost all cell populations
were transfected with the gene of interest. Our data corroborates that
NF51 is a highly efﬁcient peptide-based transfection reagent for appli-
cation in protein production and thus it can be an easy to use alternative
to electroporation that needs speciﬁc equipment.
5. Conclusions
In the current study, we demonstrated the advantage of two novel
modiﬁcations implemented to a stearyl–TP10 sequence that leads to a
highly efﬁcient transport vector for intracellular delivery of nucleic
acids. NickFect51 delivered plasmid DNA into a large variety of cell
lines, including refractory suspension and primary cells and in several
cases exceeded the transfection level of commercially available reagent
Lipofectamine™ 2000 without any cytotoxic side effects. Besides that
NickFect51 was applicable in spice correction and gene silencing. Fur-
thermore, we demonstrated that NickFect51 can be utilized in a protein
production system, QMCF technology, for expression and production of
recombinant proteins in hardly transfectable suspension cells.
Altogether our data suggests that versatile transfection reagent
NickFect51, which efﬁciently targets intracellular machineries both
in the nucleus and cytoplasm, has a great potential in gene therapy
applications and in protein production.
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